In univariate analysis, lower baseline ALT level, combined treatment of first anti-HLH regimen and subsequent anti-lymphoma regimen, achieving CR or PR were significantly related to improved OS (P=0.001, P=0.004, and P=0.009, respectively). The gene discussed is GPT; the disease is lymphoma.